BIOBETTERS: THE BETTER BIOLOGICS AND THEIR REGULATORY OVERVIEW
Journal Title: International Journal of Drug Regulatory Affairs - Year 2016, Vol 4, Issue 1
Abstract
The continuous innovation of the biopharmaceutical industry has led to development of a new category of biopharmaceuticals i.e. Biobetters or Biosuperiors. Biobetters may have better efficacy, a longer half-life, lower dosing frequency, a reduced risk of immunogenicity, reduced toxicity and side effects along with lower early-stage research risk and development costs. Biobetters rather than biosimilars may capture significant share of market and are the next wave for companies to ride on. Although it sounds intuitive, biobetters will have to face various ordeals like identification of the apparent unmet need, quantification of the potential market opportunity, expensive investment in clinical trials, challenging regulatory approval, pressures of price erosion and patent litigations. Thus, development of biobetters truly requires the right balance between providing life-changing medical management for patients and maintaining an innovative pipeline for continued business success. This review will focus on technical and regulatory prospects of biobetters.
Authors and Affiliations
Verma Sandeep, Jain Parveen, Chauhan P
Keywords
Related Articles
- EP ID EP337052
- DOI -
- Views 97
- Downloads 0
LYOPHILIZATION - PROCESS AND OPTIMIZATION FOR PHARMACEUTICALS
In this 21st century, Lyophilization emerges to be a novel trend for the drying of pharmaceuticals and biological that are thermolabile or are unstable in aqueous form but stable for longer periods in their dried form. T...
REGULATORY STRATEGY FOR REGISTRATION OF COMBINATION PRODUCTS TO US-FDA
In pharmaceutical industry all the healthcare products are categorized into Drugs, Devices, and biologics and they are regulated by their respective departments of the regulatory authorities. Due to more and more develop...
PIC/S: TRAINING THE REGULATORS TO REGULATE cGMP COMPLIANCE
PIC/S is an international Organization for implementing cGMP standards in its member countries. The basic objective of PIC/S is to improve and standardize cGMP compliance in member countries. Their aim is to enhance GMP...
FORMULATION, DEVELOPMENT AND OPTIMIZATION OF MODIFIED RELEASING PELLETS OF DRUG CARVEDILOL
The main objectives of present work was to design and evaluate modified releasing pellets of drug, Carvedilol, in respect to increase patient compliance and therapeutically benefits. The modified releasing pellets were m...
A COMPREHENSION STUDY ON REGULATION OF HERBAL DRUGS IN USA, EUROPEAN UNION AND INDIA
The present study reviews the regulations of herbal drugs in the EU, US and India and throws light upon issues related to their clinical trials. Herbal drugs have been used for a long time in different systems of health...